To date, only tacrine, donepezil, rivastigmine, and galanthamine have been approved by the FDA for AD symptomatic treatment [22] and only DON (donezepil), RIV (rivastigmine), and GAL (galantamine) are strictly known as cholinesterase inhibitors. This evidence concerns the gene GAL and Alzheimer disease.